[Preliminary results of rifabutine (ansamycine LM 427) treatment of patients with newly detected and chronic pulmonary tuberculosis and Mycobacterium infections].
Rowińska-Zakrzewska
E
E
Instytutu Gruźlicy i Chorób Płuc.
Słupek
A
A
Graczyk
J
J
Zwolska-Kwiek
Z
Z
Augustynowicz-Kopeć
E
E
Stambrowska
A
A
Byszewska
D
D
Latoś
E
E
Pilarska
A
A
Andrzejczyk
Z
Z
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects*; D017828:Rifabutin; D012294:Rifamycins / Q000627:therapeutic use*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D012294:Rifamycins; D017828:Rifabutin
Wstepne wyniki leczenia ryfabutyna (ansamycyna LM 427) chorych na nowo wykryta i przewlekła gruźlice płuc oraz na mykobakteriozy.